Filing Flows › China Pharma Holdings (CPHI) › Q1 2026
China Pharma Holdings (CPHI) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
China Pharma Holdings (CPHI) reported revenue of $984K for the first quarter 2026 (Q1 2026), -13% from a year earlier and -20% from the quarter before. Operating margin was -113.6%, net loss $1.1M (116.2% of revenue).
China Pharma Holdings, Q1 2026: revenue $984K (-13% year over year), operating margin -113.6%, net loss $1.1M, operating cash flow −$55K. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $984K | -20% | -13% |
| Operating profit | −$1.1M | — | — |
| Net earnings | −$1.1M | — | — |
| Operating cash flow | −$55K | -136% | — |
What changed
Revenue was $1.0M in Q1 2026, down 13% year over year and down 20% from the previous quarter.
Gross margin was 29.0%. Operating costs exceeded revenue by $1.1M, an operating margin of -113.6%. The fastest-growing cost line was Research & development (+183%). The quarter ended with a net loss of $1.1M, narrower than the previous quarter's $1.2M loss.
Operating cash flow was −$55K. Non-cash charges added back $1.0M of depreciation and amortization. Working capital and other items added $107K.
Questions
What was China Pharma Holdings' revenue in the first quarter 2026?
China Pharma Holdings (CPHI) reported revenue of $984K for the first quarter 2026 (Q1 2026), -13% from a year earlier and -20% from the quarter before.
Was China Pharma Holdings profitable in the first quarter 2026?
Operating loss was $1.1M (-113.6% of revenue) and net loss $1.1M.